Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose TAK-536 Pharmacokinetics in Hypertensive Children 6–<16 Years
jRCT2080222846Phase 3
- Sponsor
- Takeda
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of azilsartan in hypertension (HTN), sponsored by Takeda. Primary endpoint: Pharmacokinetic parameters of TAK-536.
02
Drugs
azilsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on jRCT2080222846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222846.